Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
about
PSA and beyond: alternative prostate cancer biomarkersVirus encoded circulatory miRNAs for early detection of prostate cancerEpigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors.Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal BiomarkersQuantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer.Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine.Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.Translational and clinical implications of the genetic landscape of prostate cancer.Novel biomarkers for the detection of prostate cancer.Long Non-Coding RNA as Potential Biomarker for Prostate Cancer: Is It Making a Difference?Recent progress and perspectives on prostate cancer biomarkers.ERG expression in prostate cancer: biological relevance and clinical implication.The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study.PBX3 is a putative biomarker of aggressive prostate cancer.Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.What's new in screening in 2015?Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.Current Management Strategy for Active Surveillance in Prostate Cancer.The potential use of urine cell free DNA as a marker for cancer.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.The role of prostate cancer biomarkers in undiagnosed men.miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.The context of prostate cancer genomics in personalized medicine.Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes.Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.Novel insights into chromosomal conformations in cancer.From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer.Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.The molecular biology of prostate cancer: current understanding and clinical implications.Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.Prostate cancer screening in Europe and Asia.The crucial role of multiomic approach in cancer research and clinically relevant outcomes.Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer.
P2860
Q26770646-1E1F09EF-FDB1-4421-BC70-6F2308181FEAQ26776424-9F0C0B1A-A99D-4DD9-A7CD-7D6074768205Q27323950-D006086C-3943-4395-B4E4-A16A202AF04EQ28075610-090D2A8B-7774-46B9-94E3-6544AB994759Q30395328-C41BAB50-4C06-4940-A6D1-C76BFC793BB4Q33890201-31E8681F-B671-4578-890E-263C43796D97Q36157852-3C179A27-67FF-4A16-952A-D3B6F29CD295Q36336025-35D53FD4-CEE0-48A0-9E8B-97336C866C4DQ37270512-85D6E303-93E2-4062-AC85-80126B0BAA15Q37708174-827D2622-597B-43FD-8B83-82B969765494Q37724539-A7C7A893-F756-43FE-89E7-44E9841A5306Q37736079-8CC982E5-8D1E-4952-8765-98CC0F02945CQ38681610-E06D189F-E43F-4F07-A2AB-8472853EB4EDQ38684598-E614C12F-C441-4344-8B2C-1B18BC9FABF5Q38765965-75C65708-D768-4001-9297-D46C96C30A04Q38786630-9CAA6AF2-E87F-4C63-B62D-B53C817B4859Q38871819-05976AAD-84AC-4A20-A614-EB376F6497D9Q38874800-DADF4D17-706B-4D0D-A2BF-448935234DFEQ38950445-0FFE260E-BE69-42AF-84CF-CC6218F062D4Q38950908-E0CA2BD2-A688-45C5-BB55-6523242197C5Q38994581-19DF8DC6-AA87-49A0-898C-DAFC93C91E28Q39108592-15263AF7-B28E-48BF-8CED-36F900A7CDDAQ39140686-C9F42D5F-BB6C-4635-8AF3-7513C1848983Q39214638-B94B1869-2282-4E94-9880-B7573DC3A979Q40461863-BD46FF95-A18A-4AA0-BE4F-23DA4171A0DFQ40461954-92561F1F-D4EC-46AB-9363-4D2938A380CFQ41212675-A3BEE71E-428B-4C18-BA12-C4D1FE0A0A42Q41839243-E8C89DE4-266A-42D7-BBB5-87231D0BB20AQ42335698-DC690887-22A8-408E-A31C-7807817FE213Q42345804-B66E91BF-5915-4F28-9122-411CC6489679Q44871406-0CA5C4B8-B85F-4373-A7D0-7A4CB20F5471Q47098649-3E8DAF2D-4B85-4D44-9491-87B21290262EQ47287055-CAB07707-3CD5-4E6D-8174-911A843C22A8Q47436741-AB5B4FF2-8343-4E66-B688-730AB535C646Q48252578-98DEEA71-98DA-404A-80C5-61C874991E34Q49546811-D2C077CF-CB3B-46BD-B3BE-F231D28E4E02Q50107743-BBD72F57-3C71-49BF-8998-8448E2AA99F2Q51771288-3FB32781-3D8F-4C9D-A2A5-6702BABA881CQ52363678-4A053A07-36AB-40B6-8A72-ECCE2EFB30C3Q52569296-4E9C18DB-8145-4E00-8F7F-0198F521B2EC
P2860
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
@en
type
label
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
@en
prefLabel
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
@en
P2093
P2860
P1433
P1476
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
@en
P2093
Arul M Chinnaiyan
Jack Groskopf
Javed Siddiqui
John R Day
John T Wei
L Priya Kunju
Petrea Hodge
Robert J Lonigro
Rodney L Dunn
Sarah Meyer
P2860
P356
10.1016/J.EURURO.2015.04.039
P407
P577
2015-05-15T00:00:00Z